The New Risk Map for Pharmaceutical Pricing

I was grateful to join Melanie Whittington, PhD on Perspectives by the Leerink Center for Pharmacoeconomics for a conversation about the U.S. Trade Representative’s Section 301 investigation into Germany’s pharmaceutical pricing and reimbursement practices. The interview can be found here.

The investigation itself is important, but I think the larger point is even more important.

The status quo is over.

Pharmaceutical companies and investors can no longer look at pricing, reimbursement, trade policy, launch planning, manufacturing, and patient access as separate issues. These areas are beginning to move together, especially for companies operating across the U.S., EU, and UK.

For a long time, pharmaceutical pricing was mostly treated as a domestic reimbursement issue. In the United States, that meant looking at Medicare, CMS, PBMs, commercial payers, the Inflation Reduction Act, and state-level access questions. In Europe, it meant looking country by country at health technology assessment, national budgets, reimbursement decisions, and launch sequencing.

Those issues still matter. They always will. The difference now is that trade policy is becoming part of the pricing conversation.

Section 301, Section 232, Most Favored Nation-style proposals, tariff discussions, and cross-border pricing arrangements are forcing companies to think differently about market strategy. A pricing decision in one country may no longer stay in that country. A reimbursement proposal in Europe may become part of a broader U.S. trade discussion. A launch strategy that once looked commercially sound may need to be reconsidered through a geopolitical and policy lens.

That is especially important because the EU is not a monolith. The European Union may operate as a commercial bloc in certain contexts, but pharmaceutical pricing and reimbursement remain deeply national. Germany, France, Italy, Spain, the Netherlands, and other countries each bring their own budget pressures, political expectations, health system priorities, and views of value.

That is why it is too simple to say that Europe is just about “price controls.” Pricing decisions are tied to clinical value, budget impact, insurance systems, patient access, politics, and long-term health system planning. Once trade policy enters that discussion, the risk map changes.

This matters for executives, boards, and investors. A company may have strong science, promising clinical data, and a compelling patient story. Those things are essential, but they are no longer enough on their own.

The company also has to explain where it will launch, how it expects to be reimbursed, what pricing assumptions support the business model, how those assumptions could change, and whether trade or policy pressure could affect the commercial plan. These questions matter even for biotech companies that are years away from commercialization because many of the assumptions about market size, pricing, access, manufacturing, and return on investment are made long before launch.

The patient access question cannot be separated from this either. If pricing and trade disputes create uncertainty, companies may delay launches, rethink markets, or narrow their commercial strategy. That can affect whether patients get access to innovative therapies, when they get access, and where that access happens first.

At the same time, policymakers are under pressure to make medicines more affordable and health systems more sustainable. That pressure is not going away.

That is why the next phase of pharmaceutical strategy requires a more connected view. Drug pricing is not only a reimbursement issue. Trade policy is not only a government relations issue. Market access is not only a commercial issue. Investor risk is not only a finance issue.

These issues now move together.

At Lanton Strategies International, we are watching these developments because they sit at the intersection of policy, reimbursement, trade, market access, and capital strategy across the U.S., EU, and UK.

For pharmaceutical companies, biotech executives, investors, and health-sector leaders, the question is not whether the rules are changing.

They are.

The work now is understanding what comes next.

Cell Therapy Is No Longer a Science Race. It’s a System Race

There was a time when cell therapy felt like a story about scientific leadership. The United States discovered it, academic centers proved it, and capital followed it. The model was familiar. Innovation started here, scaled here, and stayed here. That assumption is getting harder to hold. A recent analysis pointed to something that would have been difficult to imagine even a decade ago. China is now running more CAR-T clinical trials than the United States. That headline catches attention and sounds like a shift in scientific leadership. It is not. The science has not moved. The system has, and that distinction is where the real story begins.

Cell therapy is no longer constrained by discovery. The underlying science is increasingly validated, and the clinical signals are real. The constraint has moved. It now sits in how quickly a therapy moves from concept into a patient, how trials are structured, how fast patients are enrolled, how manufacturing is scaled, and how regulators sequence the path forward. China recognized that earlier than most and built a system that allows therapies to move into early human trials faster, often through investigator-led pathways that reduce friction at the front end. That does not mean lower standards in the long term. It means faster signal generation in the short term, and in this market, signal is everything.

Early data changes how investors see risk. It reshapes valuation, accelerates partnership discussions, and determines which programs move forward and which quietly fall away. While one system is still aligning capital, protocol, and approvals, the other is already producing patient outcomes. That gap does not stay static. It compounds. This is where the conversation begins to shift from science to capital. For years, the question was whether these therapies could work. Now the question is how quickly uncertainty can be reduced, and China’s approach compresses that uncertainty by pulling forward the moment when a therapy becomes investable.

At the same time, the United States is dealing with a different kind of pressure. The academic infrastructure that historically powered early innovation is becoming less predictable, funding dynamics are shifting, and institutional timelines are stretching. The result is a subtle but important divergence. The United States still leads in discovery, while China is gaining ground in turning that discovery into clinical momentum. Many observers frame this as a regulatory issue, though it is more accurate to think of it as a design question. The U.S. system is built to control risk before it reaches patients, prioritizing validation, standardization, and scalability. China’s system is built to surface signal earlier and refine over time. Both approaches have internal logic. What matters is how they interact with capital, because in this market capital does not wait for perfection. It moves when uncertainty drops below a certain threshold, and right now one system is reaching that threshold faster.

You can already see early signs of recalibration in the United States. Regulators are beginning to explore more flexible approaches for certain therapies, particularly in rare diseases. That is not a philosophical shift. It is a structural response to a system that is being outpaced at the front end. Which brings this back to the question executives are starting to confront, whether they say it explicitly or not. Where do you generate your first data? Where do you take your earliest risk? Where do you position your program for valuation inflection? These used to be operational decisions. They are now strategic ones.

Cell therapy is not dividing along geographic lines. It is dividing along system lines. One system continues to lead in discovery, while the other is becoming faster at execution. Over time, those lines may blur or converge into a hybrid model that takes pieces of both. The near-term risk is not that innovation leaves the United States. It is that the center of gravity for translating that innovation begins to shift, and once that shift takes hold, it becomes much harder to reverse. That is the part of the story that is easy to miss if you are only watching the headlines. Cell therapy is not just advancing. It is reorganizing around the systems that can move it forward fastest.